MAR 29, 2021
This study assessed whether the rate of geographic atrophy (GA) enlargement is influenced by subsequent exudative neovascular AMD.
Researchers performed a post hoc analysis of AREDS2. They evaluated 2 cohorts: eyes with GA at baseline and eyes that GA developed during follow-up. Stereoscopic fundus photos at baseline and annual visits were analyzed for presence and area of GA, and presence of exudative neovascular AMD. The main outcome was change over time in square root of GA area.
Of the 757 eyes that developed GA during the mean follow-up of 2.3 years, 73 (9.6%) developed subsequent exudative neovascular AMD. GA enlargement in these eyes was slower than in eyes that did not develop exudative neovascular AMD (0.20 mm/year vs 0.29 mm/year). Of 456 eyes with GA at baseline, 63 (13.8%) developed subsequent exudative neovascular AMD over a mean follow-up of 4.1 years. Lesion enlargement in these eyes was relatively similar to eyes without subsequent exudative neovascular AMD.
The study used fundus photos to measure the GA areas and detect exudative neovascular AMD instead of other imaging modalities.
In eyes that developed GA during the AREDS2 study, GA enlargement before the development of exudative neovascular AMD was slower than in eyes that did not develop AMD. This difference was not present in patients who already had GA at their baseline study visit. There may be a potential protective effect of choroidal neovascularization on the progression of GA in patients with recent onset of GA. At this point, further studies are needed to better understand this relationship before this study’s findings would change current clinical practice and treatment paradigms.